This ‘Tenosynovial Giant Cell Tumors - Epidemiology Forecast-2032' report delivers an in-depth understanding of Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as Tenosynovial Giant Cell Tumors trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Tenosynovial Giant Cell Tumors Disease Understanding
Tenosynovial giant cell tumors (TSGCTs) are a group of neoplastic disorders that involve synovium-lined tendon sheaths, synovial joints, and adjacent soft tissue. They are divided based on localized and diffused subtypes. TSGCT is an abnormal growth of tissue derived from the synovium that causes activation of immune cells, specifically macrophages, leading to the formation of a mass. These tumors are often classified by their growth pattern (localized or diffused) and location (intra-or extra-articular). These pathological distinctions are important because variability in the clinical and biological features of these neoplasms affect treatment. TSGCTs are usually benign lesions arising from the tendon sheath.Tenosynovial Giant Cell Tumors Diagnosis
A diagnosis of TSGCT is based upon the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized tests. The initial symptoms of these tumors are often vague and may go unrecognized. Consequently, there is usually a significant delay, 3-4 years on average, from the onset of symptoms until a diagnosis is made.Tenosynovial Giant Cell Tumors Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incidence of Tenosynovial Giant Cell Tumor (TSGCTs), Growth pattern-specific incidence of Tenosynovial Giant Cell Tumor (TSGCTs), Gender-specific incidence of Localized Tenosynovial Giant Cell Tumor (L-TSGCTs), Gender-specific incidence of Diffused Tenosynovial Giant Cell Tumors (D-TSGCTs), Tumor localization of Localized Tenosynovial Giant Cell Tumor (l-TSGCTs), and Tumor localization of Diffused Tenosynovial Giant Cell Tumor (D-TSGCTs) scenario of Tenosynovial Giant Cell Tumors in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.Tenosynovial Giant Cell Tumors Detailed Epidemiology Segmentation
- The total incident population of Tenosynovial Giant Cell Tumors (TSGCTs) in the 7MM was found to be 33,577 in 2021. These cases are expected to increase by 2032 at a decent CAGR during the study period (2019-2032).
- Among 7MM, the United States has the highest Incident Cases of Tenosynovial Giant Cell Tumor (TSGCTs) with 14,301 cases in 2021.
- As per our analysis the growth pattern-specific incidence of Tenosynovial Giant Cell Tumor (TSGCTs) in the 7MM were observed to be higher in localized- TSGCTs than in diffuse-TSGCTs. There were 30,249 cases of L-TSGCTs and 3,329 of D-TSGCTs in 2021 in the 7MM. These cases are expected to increase during the study period (2019-2032).
- In 2021, as per The analysis, the tumor localization of L-TSGCTs in the United States was studied for digits, knees, ankles, hips, and others and was found to be 9,667, 1,474, 352, 32, 1,346 cases respectively in the US. It was found to be highest for digits in 2021, and these cases are expected to rise during the forecasted period (2022-2032).
- The total incident population of TSGCTs in the five major European markets was 43% of the total incident population among the 7MM in 2021.
- As per our estimates, the incident cases of TSGCTs in EU-5 was 14,443 in 2021, among which Germany has the highest incident population with 3,759 cases followed by France with 2,909 cases. The lowest incident cases were observed in Spain with 2,102 cases in 2021.
Scope of the Report
- The report covers the descriptive overview of Tenosynovial Giant Cell Tumors, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden of Tenosynovial Giant Cell Tumors.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM, Incidence of Tenosynovial Giant Cell Tumor (TSGCTs), Growth pattern-specific incidence of Tenosynovial Giant Cell Tumor (TSGCTs), Gender-specific incidence of Localized Tenosynovial Giant Cell Tumor (L-TSGCTs), Gender-specific incidence of Diffused Tenosynovial Giant Cell Tumors (D-TSGCTs), Tumor localization of Localized Tenosynovial Giant Cell Tumor (L-TSGCTs), and Tumor localization of Diffused Tenosynovial Giant Cell Tumor (D-TSGCTs).
Report Highlights
- 11-Year Forecast of Tenosynovial Giant Cell Tumors.
- The 7MM Coverage.
- Total incident cases of Tenosynovial Giant Cell Tumors.
- Growth pattern-specific incidence of Tenosynovial Giant Cell Tumors.
- Gender-specific incidence of Localized Tenosynovial Giant Cell Tumor (L-TSGCTs).
- Gender-specific incidence of Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs).
- Tumor localization of Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs)
- Tumor localization of Localized Tenosynovial Giant Cell Tumor (L-TSGCTs)
Key Questions Answered
- What are the disease risk and burdens of Tenosynovial Giant Cell Tumors?
- What is the historical Tenosynovial Giant Cell Tumors patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Tenosynovial Giant Cell Tumors at the 7MM level?
- What will be the growth opportunities across the 7MM concerning the patient population for Tenosynovial Giant Cell Tumors?
- Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Tenosynovial Giant Cell Tumors during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Reasons to Buy
The Tenosynovial Giant Cell Tumors report will allow the user to -- Develop business strategies by understanding the trends shaping and driving the 7MM Tenosynovial Giant Cell Tumors epidemiology forecast.
- The Tenosynovial Giant Cell Tumors epidemiology report and model were written and developed by Master and Ph.D. level epidemiologists.
- The Tenosynovial Giant Cell Tumors epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation.
- Disease Risk and Burden.
- Risk of disease by the segmentation.
- Factors driving growth in a specific patient population.
Geographies Covered
- The United States.
- EU5 (Germany, France, Italy, Spain, and the United Kingdom).
- Japan.
Table of Contents
1. Key Insights2. Report Introduction3. Executive Summary of Tenosynovial Giant Cell Tumors (TSGCT)6. Key Opinion Leaders' Views8. Publisher Capabilities9. Disclaimer
4. Tenosynovial Giant Cell Tumors: Disease Background and Overview
5. Epidemiology and Patient Population
7. Appendix
List of Tables
List of Figures
